Takeda's Entyvio Defends Share Against Janssen's Stelara in the Crohn's Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer's Xeljanz Secures an FDA Win

EXTON, Pa., Nov. 21, 2017 /PRNewswire/ -- A survey of over 100 US gastroenterologists fielded in late October 2017 indicates that, in both the ulcerative colitis (UC) and Crohn's Disease (CD) markets, the established TNF inhibitors, Remicade and AbbVie's Humira, persistently dominate...